These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). Maurer MS; Hanna M; Grogan M; Dispenzieri A; Witteles R; Drachman B; Judge DP; Lenihan DJ; Gottlieb SS; Shah SJ; Steidley DE; Ventura H; Murali S; Silver MA; Jacoby D; Fedson S; Hummel SL; Kristen AV; Damy T; Planté-Bordeneuve V; Coelho T; Mundayat R; Suhr OB; Waddington Cruz M; Rapezzi C; J Am Coll Cardiol; 2016 Jul; 68(2):161-72. PubMed ID: 27386769 [TBL] [Abstract][Full Text] [Related]
11. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Phull P; Sanchorawala V; Connors LH; Doros G; Ruberg FL; Berk JL; Sarosiek S Amyloid; 2018 Mar; 25(1):62-67. PubMed ID: 29424556 [TBL] [Abstract][Full Text] [Related]
12. Importance of genetic study in elderly patients with transthyretin cardiac amyloidosis. Gallego Delgado M; Gayán Ordás J; Eiros R; García Berrocal B; Sánchez PL; Villacorta E Med Clin (Barc); 2023 Nov; 161(9):382-385. PubMed ID: 37532616 [TBL] [Abstract][Full Text] [Related]
13. Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy? Aus dem Siepen F; Hein S; Prestel S; Baumgärtner C; Schönland S; Hegenbart U; Röcken C; Katus HA; Kristen AV Clin Res Cardiol; 2019 Dec; 108(12):1324-1330. PubMed ID: 30953182 [TBL] [Abstract][Full Text] [Related]
14. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model. Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196 [TBL] [Abstract][Full Text] [Related]
15. Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope. González-López E; López-Sainz Á; Garcia-Pavia P Rev Esp Cardiol (Engl Ed); 2017 Nov; 70(11):991-1004. PubMed ID: 28870641 [TBL] [Abstract][Full Text] [Related]
16. Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis. Gopal DM; Ruberg FL; Siddiqi OK Curr Heart Fail Rep; 2019 Oct; 16(5):180-188. PubMed ID: 31520266 [TBL] [Abstract][Full Text] [Related]
17. Frequencies and geographic distributions of genetic mutations in transthyretin- and non-transthyretin-related familial amyloidosis. Zhen DB; Swiecicki PL; Zeldenrust SR; Dispenzieri A; Mauermann ML; Gertz MA Clin Genet; 2015 Oct; 88(4):396-400. PubMed ID: 25211232 [TBL] [Abstract][Full Text] [Related]
18. Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy. Koike H; Ando Y; Ueda M; Kawagashira Y; Iijima M; Fujitake J; Hayashi M; Yamamoto M; Mukai E; Nakamura T; Katsuno M; Hattori N; Sobue G J Neurol Sci; 2009 Dec; 287(1-2):178-84. PubMed ID: 19709674 [TBL] [Abstract][Full Text] [Related]
19. Upper limb neuropathy such as carpal tunnel syndrome as an initial manifestation of ATTR Val30Met familial amyloid polyneuropathy. Tojo K; Tsuchiya-Suzuki A; Sekijima Y; Morita H; Sumita N; Ikeda S Amyloid; 2010 Mar; 17(1):32-5. PubMed ID: 20132088 [TBL] [Abstract][Full Text] [Related]
20. RNA-targeting and gene editing therapies for transthyretin amyloidosis. Aimo A; Castiglione V; Rapezzi C; Franzini M; Panichella G; Vergaro G; Gillmore J; Fontana M; Passino C; Emdin M Nat Rev Cardiol; 2022 Oct; 19(10):655-667. PubMed ID: 35322226 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]